ORIC Pharmaceuticals has received FDA approval for the first clinical trial of ORIC-533. It is an inhibitor of the substance CD-73, which controls the rate of creation of extracellular adenosine, which can improve the effectiveness of chemotherapy and immunotherapy. Phase I clinical trials of ORIC-533 are scheduled to begin in the second half of 2021.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept